These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36007339)

  • 21. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
    Meher BR; Mohanty RR; Dash A
    Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
    Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
    Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
    Paton DM
    Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
    Uzawa A; Mori M; Iwai Y; Masuda H; Kuwabara S
    Intern Med; 2022 Sep; 61(18):2785-2787. PubMed ID: 35135926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
    Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
    Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Satralizumab: First Approval.
    Heo YA
    Drugs; 2020 Sep; 80(14):1477-1482. PubMed ID: 32797372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Mult Scler Relat Disord; 2022 Sep; 65():104037. PubMed ID: 35835028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
    J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Pittock SJ; Fujihara K; Palace J; Berthele A; Kim HJ; Oreja-Guevara C; Nakashima I; Levy M; Shang S; Yountz M; Miller L; Armstrong R; Wingerchuk DM;
    Mult Scler; 2022 Mar; 28(3):480-486. PubMed ID: 34498507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).
    Lee ST; Abboud H; Irani SR; Nakajima H; Piquet AL; Pittock SJ; Yeh EA; Wang J; Rajan S; Overell J; Smith J; St Lambert J; El-Khairi M; Gafarova M; Gelfand JM
    Front Neurol; 2024; 15():1437913. PubMed ID: 39193150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapies for neuromyelitis optica spectrum disorder.
    Levy M; Fujihara K; Palace J
    Lancet Neurol; 2021 Jan; 20(1):60-67. PubMed ID: 33186537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder.
    Magro G
    Clin Immunol; 2022 Aug; 241():109072. PubMed ID: 35798242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.